SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/55870"
 

Search: onr:"swepub:oai:gup.ub.gu.se/55870" > Cardiovascular morb...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Franklin, S. S. (author)

Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy

  • Article/chapterEnglish2005

Publisher, publication year, extent ...

  • 2005

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/55870
  • https://gup.ub.gu.se/publication/55870URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • We hypothesized that losartan was superior to atenolol in reducing cardiovascular events in a lower-risk group (LRG) versus a higher-risk group (HRG) of patients in a Losartan Intervention For Endpoint reduction (LIFE) substudy, independently of blood pressure (BP) reduction. In a post hoc analysis, we designated 4282 patients as LRG on the basis of: (1) no previous cardiovascular disease (coronary, cerebral, peripheral vascular disease); (2) no diabetes; (3) no isolated systolic hypertension; and (4) inclusion of the lowest 3 quartiles of electrocardiographically documented left ventricular hypertrophy. The HRG consisted of 4911 remaining patients who did not qualify for the LRG. In the LRG, losartan was superior to atenolol in reducing stroke: hazard ratio (HR), 0.72 (95% confidence interval [CI], 0.53 to 0.98); new-onset diabetes (HR, 0.74 [95% CI, 0.58 to 0.93]; and new-onset atrial fibrillation: HR, 0.69 (95% CI, 0.51 to 0.92), all P<0.05 but not composite end points or cardiovascular mortality (both P=NS). In the HRG, losartan was superior to atenolol in reducing composite end points: HR, 0.82 (95% CI, 0.71 to 0.94), P<0.01; cardiovascular mortality: HR, 0.77 (95% CI, 0.62 to 0.95), P<0.05; stroke: HR, 0.75 (95% CI, 0.61 to 0.92), P<0.01; new-onset diabetes: HR, 0.76 (95% CI, 0.60 to 0.96), P<0.05; and new-onset atrial fibrillation: HR, 0.71 (95% CI, 0.58 to 88), P<0.05. Test for interaction of treatment with LRG versus HRG was not significant for composite end point, stroke, or atrial fibrillation, but was for cardiovascular mortality (P=0.018). Achieved systolic BP reduction favored losartan over atenolol by -1.8 mm Hg in LRG (P=NS) and -0.7 mm Hg (P=0.001) in HRG, but no significant differences occurred in diastolic or mean BP in either group. In conclusion, losartan compared with atenolol reduces the risk of stroke, new-onset diabetes, and new-onset atrial fibrillation in the LRG and the HRG.

Subject headings and genre

  • Adrenergic beta-Antagonists/*therapeutic use
  • Aged
  • 80 and over
  • Angiotensin II Type 1 Receptor Blockers/therapeutic use
  • Animals
  • Atenolol/*therapeutic use
  • Atrial Fibrillation/prevention & control
  • Blood Pressure/*drug effects
  • Cardiovascular Diseases/*complications/*mortality
  • Cerebrovascular Accident/prevention & control
  • Diabetes Mellitus/prevention & control
  • Female
  • Humans
  • Hypertension/*complications/drug therapy/physiopathology
  • Losartan/*therapeutic use
  • Male
  • Middle Aged
  • Randomized Controlled Trials
  • Risk

Added entries (persons, corporate bodies, meetings, titles ...)

  • Wachtell, K. (author)
  • Papademetriou, V. (author)
  • Olsen, M. H. (author)
  • Devereux, R. B. (author)
  • Fyhrquist, F. (author)
  • Ibsen, H. (author)
  • Kjeldsen, S. E. (author)
  • Dahlöf, Björn,1953Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute(Swepub:gu)xdahbj (author)
  • Göteborgs universitetHjärt-kärlinstitutionen (creator_code:org_t)

Related titles

  • In:Hypertension46:3, s. 492-91524-4563

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view